GIA
NTLA icon

GHP Investment Advisors’s Intellia Therapeutics NTLA Stock Holding History

GHP Investment Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85 Sell
5
-45
-90% -$630 ﹤0.01% 1297
2026
Q1 		$641 Hold
50
– – ﹤0.01% 1085
2025
Q4 		$450 Buy
+50
New +$688 ﹤0.01% 942

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

GHP Investment Advisors's NTLA Position: Q2 2026 in Review

GHP Investment Advisors reduced its Intellia Therapeutics (NTLA) stake by 90% in Q2 2026, selling an estimated $630 and leaving 5 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #1297.

GHP Investment Advisors first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. The position peaked at $641 in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • GHP Investment Advisors held 5 shares of Intellia Therapeutics worth $85 as of Q2 2026.
  • GHP Investment Advisors sold 45 Intellia Therapeutics shares in Q2 2026, an estimated $630.
  • Intellia Therapeutics made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #1297 holding.
  • GHP Investment Advisors first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • GHP Investment Advisors's Intellia Therapeutics position peaked at $641 in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.